ArticleTherapeutic advances in endocrinology and metabolism2026
Association of insulin resistance-related indicators with cardiovascular disease and cardiovascular disease mortality in individuals with MASLD: a population-based study.
Article in Therapeutic advances in endocrinology and metabolism, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- A cardiometabolic risk phenotype index integrating insulin resistance, systemic inflammation, and psychological burden for mortality risk stratification in metabolic dysfunction-associated steatotic liver disease: an exploratory longitudinal analysis of a nationally representative cohort.Lipids in health and disease · 2026Article
- Helicobacter pylori and Porphyromonas gingivalis as candidate microbial biomarkers linking periodontal disease, MASLD, and cardiovascular risk.Infection · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Limited studies have explored the relationship between surrogate markers of insulin resistance (IR) with both cardiovascular disease (CVD) risk and CVD mortality in individuals with metabolic dysfunction-associated fatty liver disease (MASLD). This study aimed to assess the associations of various IR surrogates with CVD risk and mortality and to identify effective predictors of cardiovascular outcomes in this population. Design: This study constituted a population-based cross-sectional investigation, utilizing data derived from six cycles of the National Health and Nutrition Examination Survey (NHANES) spanning from 2005 to 2016. The data were linked to the NHANES public-use linked mortality files up to December 31, 2019, to facilitate follow-up on CVD mortality. Following predefined exclusion criteria, participants diagnosed with MASLD were identified and incorporated into the study. The research assessed the associations between surrogate markers of IR and both the prevalence of CVD and CVD mortality. Methods: The primary outcome of this study was the incidence of CVD in individuals with MASLD, and the secondary outcome was CVD mortality. Weighted multivariate logistic regression was utilized to examine the relationship between surrogate markers of IR with total CVD and other subtypes. Weighted multivariate Cox regression and Kaplan-Meier analysis were used to examine the relationship between surrogate markers of IR and CVD mortality. Restricted cubic spline (RCS) was used to explore potential nonlinear relationships. Receiver operating characteristics (ROC) and calibration curves were plotted to evaluate the discriminability and accuracy of IR surrogate markers in predicting CVD risk. Furthermore, mediation analysis was conducted to determine whether surrogate markers of liver fibrosis play a mediating role in the association of surrogate markers of IR with the risk of total CVD and other subtypes. Results: This study suggests that in the fully adjusted model, estimated glucose disposal rate (eGDR) was significantly negatively correlated with total CVD, congestive heart failure (CHF), heart attack (HA), and CVD mortality. Metabolic score for IR and triglyceride-glucose-body mass index were significantly positively correlated with CVD mortality, total CVD, and CHF. eGDR was best correlated with total CVD (odds ratio (OR) = 0.40, 95% confidence interval (CI): 0.25, 0.63), CHF (OR = 0.15, 95% CI: 0.06, 0.38), and HA (OR = 0.40, 95% CI: 0.22, 0.71). Weighted multivariate Cox regression indicated that for each unit increase in eGDR, the risk of CVD mortality decreased by 27%. RCS analysis showed that all surrogate markers of IR were linearly related to CVD and CVD mortality ( Conclusion: In conclusion, eGDR outperformed other IR surrogates in predicting both CVD risk and CVD mortality in MASLD. Incorporating eGDR into prediction models may enhance risk stratification and facilitate early identification of high-risk individuals in this population. Further studies are warranted to validate these findings in external cohorts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.